Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers

Despite numerous advances in targeted therapy and immunotherapy in the last decade, lung cancer continues to present the highest mortality rate of all cancers. Targeted therapy based on specific genomic alterations, together with PD-1 and CTLA-4 axis blocking-based immunotherapy, have significantly...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Xabier Mielgo-Rubio, Virginia Calvo, Javier Luna, Jordi Remon, Margarita Martín, Pedro Berraondo, José Ramón Jarabo, Oliver Higuera, Esther Conde, Javier De Castro, Mariano Provencio, Florentino Hernando Trancho, Fernando López-Ríos, Felipe Couñago
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MDPI AG 2020-11-01
Reeks:Cancers
Onderwerpen:
immunotherapy
early-stage
non-small cell lung cancer
biomarkers
PD-1
nivolumab
Online toegang:https://www.mdpi.com/2072-6694/12/11/3459
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items